The therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use.
Objective: To summarize the clinical outcomes, study designs and limitations for the use of CBD and nabiximols (whole plant extract from Cannabis sativa L. that has been purified into 1:1 ratio of CBD and delta-9- tetrahydrocannabinol) in the treatment of psychiatric disorders.
SCC Member Gretchen E. Maurer, DO, MS and colleagues examine the current research potential for cannabis in sports medicine.
Author: Ethan B. Russo Published in: Frontiers in Integrative Neuroscience October 2018 Abstract Introduction: Cannabis burst across the Western medicine horizon after its introduction by William O’Shaughnessy in 1838 (O’Shaughnessy, 1838–1840;…
Authors: María Fernández-Trapero, Carmen Pérez-Díaz, Francisco Espejo-Porras, Eva de Lago, Javier Fernández-Ruiz Published in Biomolecules February 2020 Abstract The phytocannabinoid-based medicine Sativex® is currently marketed for the treatment of spasticity and…